Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 immunobridging study of RSVPreF3 OA vaccine in Chinese adults aged 18-59 years at increased risk for RSV disease
CTR20253232Phase 3Active
- Sponsor
- GSK
- Start
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of GSK3003899A in respiratory syncytial virus disease (RSV), pulmonary infection, sponsored by GSK. Started Oct 2025; status: active.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)pulmonary infection
Beyond the preview
Go deeper on CTR20253232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253232.